Prostate Cancer Diagnostics and Treatment Market: Global Industry Analysis and Forecast (2023-2029)


Prostate Cancer Diagnostics and Treatment Market is expected to grow at a CAGR of 6.5% during the forecast period and the market size is expected to reach nearly US$ 9.20 Bn by 2029.

Prostate Cancer Diagnostics and Treatment Market Overview:

One of the most common types of cancer is prostate cancer. Many prostate cancers are slow-growing and limited to the prostate gland, where they are unlikely to cause substantial harm. The majority of prostate malignancies are discovered through screening. Early prostate tumours rarely generate symptoms; however, symptoms caused by more advanced tumours can lead to their discovery.Prostate Cancer Diagnostics and Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Prostate Cancer Diagnostics and Treatment Market Dynamics:

Rising cases of Prostate Cancer worldwide is expected to majorly drive the market growth during forecast period.

One of the key factors driving demand for diagnostic tools is the rising prevalence of prostate cancer. According to the National Cancer Institute, around 174,650 new cases of cancer were identified in the United States in 2021. The primary drivers fuelling the market in the forecast period are increased attention on the illness burden and increased knowledge about the disease. Diagnostics for prostate cancer are critical for early identification and effective therapy of the illness. Prostate cancer is becoming more common, the geriatric population is growing, there are more investments in the field of prostate cancer diagnostics, and there is a growing awareness of the disease's early diagnosis. The Australian government and the Movember Foundation announced a partnership to fight prostate cancer in 2021, spending AUD 12 million in ground-breaking new research teams dedicated to undertaking life-saving prostate cancer research and reducing the number of fatalities caused by the disease.

During the forecast period, technological developments in diagnostic tests are projected to boost market growth even further. Researchers are currently studying the use of Artificial Intelligence (AI) to identify prostate cancer, according to the National Cancer Institute. Artificial intelligence (AI) is used to identify questionable spots identified during an MRI scan that require biopsies to confirm the presence of malignant cells. Another factor that is expected to fuel the growth of the prostate cancer diagnostics market in the near future is the increasing number of new market entrants. Gregor Diagnostics, for example, committed USD 9, 00,000 in July 2021 to boost its attempts to create a unique at-home screening test. In comparison to standard PSA testing, this device is predicted to provide very sensitive test findings.

The report has profiled nineteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Prostate Cancer Diagnostics and Treatment Market Segment Analysis:

The Prostate Cancer Diagnostics and Treatment Market is segmented on the basis of Type, Diagnosis and Treatment.

Based on Diagnosis, the Transrectal Ultrasound segment is anticipated to dominate the global market during the forecast period. The Transrectal ultrasound (TRUS) guided biopsy is another popular diagnostic method for prostate cancer that is still regarded as a feasible option. It is rapid and convenient for the provider, with a method that most urologists are familiar with and a low risk of urine retention. TRUS is a good choice with clinical benefits for patients who cannot have MRI procedures owing to claustrophobia, metal implants, or a lack of insurance coverage. The TRUS biopsy, which is the most popular and useful alternative transperineal method, has been endorsed by the American Urology Association and the European Association of Urology in recent years. Patients with related disorders are frequently treated with TURS biopsy, which has a significant advantage over other treatments. As a result, it is widely known and recognised.

In 2021, PCA3 held the largest market share in diagnostic testing. It's a biomarker that can help improve the accuracy of a prostate cancer diagnosis. Due to its relatively high sensitivity and specificity during diagnostic procedures, the biomarker is recommended.

Based on Treatment, the Therapeutics segment is expected to hold dominant market share xx% by 2029. The segment is further divided into Hormonal Therapy, Chemotherapy and Other Treatments. Hormone therapy is a medication that prevents your body from manufacturing testosterone, the male hormone. Testosterone is required for prostate cancer cells to proliferate. Cancer cells may die or develop more slowly if their testosterone supply is cut off. In the year 2021, the hormone therapy sector dominated the market, accounting for 31.65% of the total market share. The rise in prostate cancer prevalence, an increase in demand for hormone therapy, promising pipeline medications, and the evolving treatment of prostate cancer treatment are all contributing to this trend. Hormone therapy is occasionally used before radiation therapy to treat prostate cancer that hasn't spread. It aids in the reduction of tumour size and improves the efficiency of radiation therapy.

Regional Insights:

North America is expected to account for larger market share during forecast years.

Owing to factors such as rising prostate cancer prevalence, more awareness, and more research and development in this region, North America is expected to dominate the market share. According to the American Cancer Society, there were estimated to be 164,690 new prostate cancer cases and 29,430 deaths in the United States in 2021. The market dominance is owing to the higher acceptance of advanced technologies, well-established healthcare diagnostic facilities, the surging incidence of prostate cancer, and the enactment of numerous initiatives for raising awareness about the disease in the region.

APAC is expected to witness lucrative growth during forecast period.

Due to rising knowledge of prostate cancer treatment and adoption of prostate cancer treatment products, Asia-Pacific delivers the attractive potential for key players in the prostate cancer treatment market. Furthermore, developments in healthcare infrastructure, an increase in the number of hospitals with superior medical facilities, a growing R&D sector, increased healthcare reforms, and technical breakthroughs in the field of healthcare all contribute to market growth. Other factors driving the growth of the prostate cancer treatment market in Asia-Pacific include leading manufacturers' increased focus on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, a large population base, and high disposable incomes.

The report also helps in understanding Global Prostate Cancer Diagnostics and Treatment Market dynamics, structure by analyzing the market segments and project the Global Prostate Cancer Diagnostics and Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Prostate Cancer Diagnostics and Treatment Market make the report investor’s guide.

Prostate Cancer Diagnostics and Treatment Market Key Developments:

• Biograph Vision Quadra Extended Axial FoV PET/CT Scanner was launched by Siemens Healthcare GmbH in October 2021. This scanner is the most sensitive extended field view scanner in the business, and it's designed for clinical and research use. The product has a wide range of clinical applications and will enhance demand for cancer diagnostic procedures, as well as the company's revenue.

Prostate Cancer Diagnostics and Treatment Market Scope: Inquire before buying






Prostate Cancer Diagnostics and Treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 5.92 Bn.




Forecast Period 2023 to 2029 CAGR:
6.5%
Market Size in 2029:
US $ 9.20Bn.




 Segments Covered:
by Type
Benign Prostatic Hyperplasia
Prostatic Adenocarcinoma
Small Cell Carcinoma
Other Types




by Diagnosis
Tissue Biopsy
Transrectal Ultrasound
PCA3




by Treatment
Surgery
Radiation Therapy
Therapeutics
Hormone Therapy
Chemotherapy
Other Treatments






Prostate Cancer Diagnostics and Treatment Market By Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Prostate Cancer Diagnostics and Treatment Market Key players

1. MDx Health
2. Myriad Genetics, Inc.
3. Abbott Laboratories
4. F. Hoffman-La Roche AG
5. Genomic Health
6. Siemens Healthcare GmbH
7. OPKO Health, Inc.
8. Beckman Coulter, Inc.
9. Biomérieux SA
10.Diasorin S.P.A.
11.ACON Laboratories, Inc.
12.HUMASIS
13.Teco Diagnostics
14.Hologic Inc.
15.Accuquik Test Kits
16.Metamark Genetics, Inc.
17.Prostatype Genomics
18.Fujirebio
19.Proteomedix

Frequently Asked Questions:

1. Which region has the largest share in Global Prostate Cancer Diagnostics and Treatment Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Prostate Cancer Diagnostics and Treatment Market?
Ans: The Global Prostate Cancer Diagnostics and Treatment Market is growing at a CAGR of 6.5% during forecasting period 2023-2029.

3. What is scope of the Global Prostate Cancer Diagnostics and Treatment market report?
Ans: Global Prostate Cancer Diagnostics and Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Prostate Cancer Diagnostics and Treatment market?
Ans: The important key players in the Global Prostate Cancer Diagnostics and Treatment Market are – MDx Health, Myriad Genetics, Inc., Abbott Laboratories, F. Hoffman-La Roche AG, Genomic Health, Siemens Healthcare GmbH, OPKO Health, Inc., Beckman Coulter, Inc., Biomérieux SA, Diasorin S.P.A., ACON Laboratories, Inc., HUMASIS, Teco Diagnostics, Hologic Inc., Accuquik Test Kits, Metamark Genetics, Inc., Prostatype Genomics, Fujirebio, and Proteomedix

5. What is the study period of this market?
Ans: The Global Prostate Cancer Diagnostics and Treatment Market is studied from 2022 to 2029. 




1. Preface
1.1. Market Definition and Key Research Objectives
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Prostate Cancer Diagnostics and Treatment Market Size, by Market Value (US$ Mn)
3.1. Global Market Segmentation
3.2. Global Market Segmentation Share Analysis, 2022
3.2.1. Global
3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
3.3. Geographical Snapshot of the Prostate Cancer Diagnostics and Treatment Market
3.4. Geographical Snapshot of the Prostate Cancer Diagnostics and Treatment Market, By Manufacturer share
4. Global Prostate Cancer Diagnostics and Treatment Market Overview, 2022-2029
4.1. Market Dynamics
4.1.1. Drivers
4.1.1.1. Global
4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.2. Restraints
4.1.2.1. Global
4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.3. Opportunities
4.1.3.1. Global
4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.4. Challenges
4.1.4.1. Global
4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.5. Industry Trends and Emerging Technologies
4.1.6. Porters Five Forces Analysis
4.1.6.1. Threat of New Entrants
4.1.6.2. Bargaining Power of Buyers/Consumers
4.1.6.3. Bargaining Power of Suppliers
4.1.6.4. Threat of Substitute Products
4.1.6.5. Intensity of Competitive Rivalry
4.1.7. Value Chain Analysis
4.1.8. Technological Roadmap
4.1.9. Regulatory landscape
4.1.10. Impact of the Covid-19 Pandemic on the Global Prostate Cancer Diagnostics and Treatment Market
5. Supply Side and Demand Side Indicators
6. Global Prostate Cancer Diagnostics and Treatment Market Analysis and Forecast, 2022-2029
6.1. Global Prostate Cancer Diagnostics and Treatment Market Size & Y-o-Y Growth Analysis.
7. Global Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
7.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
7.1.1. Benign Prostatic Hyperplasia
7.1.2. Prostatic Adenocarcinoma
7.1.3. Small Cell Carcinoma
7.1.4. Other Types
7.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
7.2.1. Tissue Biopsy
7.2.2. Transrectal Ultrasound
7.2.3. PCA3
7.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
7.3.1. Surgery
7.3.2. Radiation Therapy
7.3.3. Therapeutics
7.3.3.1. Hormone Therapy
7.3.3.2. Chemotherapy
7.3.3.3. Other Treatments

8. Global Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, By Region
8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029
8.1.1. North America
8.1.2. Europe
8.1.3. Asia-Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9. North America Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
9.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
9.1.1. Benign Prostatic Hyperplasia
9.1.2. Prostatic Adenocarcinoma
9.1.3. Small Cell Carcinoma
9.1.4. Other Types
9.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
9.2.1. Tissue Biopsy
9.2.2. Transrectal Ultrasound
9.2.3. PCA3
9.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
9.3.1. Surgery
9.3.2. Radiation Therapy
9.3.3. Therapeutics
9.3.3.1. Hormone Therapy
9.3.3.2. Chemotherapy
9.3.3.3. Other Treatments
10. North America Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, By Country
10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
10.1.1. US
10.1.2. Canada
10.1.3. Mexico
11. U.S. Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
11.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
11.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
11.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
12. Canada Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
12.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
12.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
12.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
13. Mexico Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
13.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
13.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
13.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
14. Europe Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
14.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
14.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
14.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
15. Europe Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, By Country
15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
15.1.1. U.K
15.1.2. France
15.1.3. Germany
15.1.4. Italy
15.1.5. Spain
15.1.6. Sweden
15.1.7. CIS Countries
15.1.8. Rest of Europe
16. U.K. Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
16.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
16.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
16.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
17. France Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
17.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
17.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
17.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
18. Germany Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
18.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
18.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
18.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
19. Italy Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
19.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
19.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
19.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
20. Spain Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
20.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
20.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
20.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
21. Sweden Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
21.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
21.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
21.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
22. CIS Countries Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
22.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
22.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
22.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
23. Rest of Europe Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
23.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
23.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
23.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
24. Asia Pacific Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
24.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
24.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
24.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
25. Asia Pacific Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, by Country
25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
25.1.1. China
25.1.2. India
25.1.3. Japan
25.1.4. South Korea
25.1.5. Australia
25.1.6. ASEAN
25.1.7. Rest of Asia Pacific
26. China Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
26.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
26.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
26.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
27. India Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
27.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
27.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
27.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
28. Japan Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
28.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
28.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
28.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
29. South Korea Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
29.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
29.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
29.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
30. Australia Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
30.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
30.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
30.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
31. ASEAN Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
31.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
31.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
31.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
32. Rest of Asia Pacific Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
32.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
32.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
32.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
33. Middle East Africa Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
33.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
33.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
33.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
34. Middle East Africa Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, by Country
34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
34.1.1. South Africa
34.1.2. GCC Countries
34.1.3. Egypt
34.1.4. Nigeria
34.1.5. Rest of ME&A
35. South Africa Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
35.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
35.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
35.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
36. GCC Countries Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
36.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
36.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
36.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
37. Egypt Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
37.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
37.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
37.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
38. Nigeria Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
38.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
38.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
38.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
39. Rest of ME&A Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
39.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
39.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
39.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
40. South America Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
40.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
40.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
40.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
41. South America Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, by Country
41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
41.1.1. Brazil
41.1.2. Argentina
41.1.3. Rest of South America
42. Brazil Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
42.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
42.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
42.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
43. Argentina Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
43.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
43.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
43.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
44. Rest of South America Prostate Cancer Diagnostics and Treatment Market Analysis and Forecasts, 2022-2029
44.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029
44.2. Market Size (Value) Estimates & Forecast By Diagnosis, 2022-2029
44.3. Market Size (Value) Estimates & Forecast By Treatment, 2022-2029
45. Competitive Landscape
45.1. Geographic Footprint of Major Players in the Global Prostate Cancer Diagnostics and Treatment Market
45.2. Competition Matrix
45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment
45.2.2. New Product Launches and Product Enhancements
45.2.3. Market Consolidation
45.2.3.1. M&A by Regions, Investment and Verticals
45.2.3.2. M&A, Forward Integration and Backward
Integration
45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
45.3. Company Profile : Key Players
45.3.1. MDx Health
45.3.1.1. Company Overview
45.3.1.2. Financial Overview
45.3.1.3. Geographic Footprint
45.3.1.4. Product Portfolio
45.3.1.5. Business Strategy
45.3.1.6. Recent Developments
45.3.2. Myriad Genetics, Inc.
45.3.3. Abbott Laboratories
45.3.4. F. Hoffman-La Roche AG
45.3.5. Genomic Health
45.3.6. Siemens Healthcare GmbH
45.3.7. OPKO Health, Inc.
45.3.8. Beckman Coulter, Inc.
45.3.9. Biomérieux SA
45.3.10. Diasorin S.P.A.
45.3.11. ACON Laboratories, Inc.
45.3.12. HUMASIS
45.3.13. Teco Diagnostics
45.3.14. Hologic Inc.
45.3.15. Accuquik Test Kits
45.3.16. Metamark Genetics, Inc.
45.3.17. Prostatype Genomics
45.3.18. Fujirebio
45.3.19. Proteomedix
46. Primary Key Insights
  • INQUIRE BEFORE BUYING